FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

AstraZeneca Discontinuing Lumoxiti for Hairy Cell Leukemia

[ Price : $8.95]

AstraZeneca says it is permanently discontinuing sales of Lumoxiti (moxetumomab pasudotox-tdfk) for injection, indicated for treat...

FDA/CDC Dismiss Signal with Pfizer Bivalent Vaccine

[ Price : $8.95]

FDA and CDC dismiss a recent potential safety signal suggesting Pfizers bivalent Covid-19 vaccine may cause ischemic stroke in peo...

Guide on Drug Dosage and Administration Labeling

[ Price : $8.95]

Federal Register notice: FDA posts a draft guidance entitled Dosage and Administration Section of Labeling for Human Prescription ...

Digital Sleep Disturbance Devices are Class 2

[ Price : $8.95]

Federal Register notice: FDA classifies digital therapy devices used to reduce sleep disturbance for psychiatric conditions into C...

5 Observations in Alembic FDA Inspection

[ Price : $8.95]

Indias BQ Prime financial news platform discloses five observations from an FDA inspection at an Alembic Pharmaceuticals non-steri...

Stop Trying to Prevent Covid in Healthy People: Offit

[ Price : $8.95]

FDA vaccines advisory committee member Paul Offit says the U.S. should stop trying to prevent symptomatic Covid infections in heal...

Dosage and Administration Label Section Guidance

[ Price : $8.95]

FDA publishes a guidance to help applicants prepare the Dosage and Administration section of labeling for prescription drug and bi...

Minor Updates to 2 Covid Test Guidances

[ Price : $8.95]

FDA announces updates to two Covid-19 testing guidances.

Qualigen Therapeutics Gains Orphan Drug Designation

[ Price : $8.95]

FDA grants Qualigen Therapeutics an orphan drug designation for QN-302 and its use in treating pancreatic cancer.

Oramed Shelves Diabetes Drug After Phase 3 Miss

[ Price : $8.95]

Oramed Pharmaceuticals discontinues clinical development of its Type 2 diabetes drug ORMD-0801 after a Phase 3 clinical trial miss...